# US 2011/0085982 A1 · Dkat cell line, a model for human triple-negative breast cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0085982 A1
- Document ID: US20110085982A1
- Status: Published application
- Kind: A1
- Application number: 12/901,292
- Filed: 2010-10-08
- Published: 2011-04-14
- Earliest claimed: 2009-10-09
- Assignees: Duke University; The Regents of the University of California
- Inventors: Victoria L. Seewaldt; Nicholas C. D'Amato; Julie H. Ostrander
- Web page: https://patentgrep.com/patent/US20110085982A1

## CPC

- G01N 33/5011: {for testing antineoplastic activity}
- C12N 5/0693: {Tumour cells; Cancer cells}
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A01K 2207/12: Animals modified by administration of exogenous cells
- A01K 2267/0331: Animal model for proliferative diseases
- C12N 2503/02: Drug screening
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/158: Expression markers
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

## Abstract

The present invention provides a human triple-negative breast cancer cell line designated DKAT. The DKAT cell line has a marker profile of high expression of Snail-1 and Snail-2 (Slug); and a p53 mutation in exon 8 at codon 273 (CGT>CAT). The present invention further provides methods of using the DKAT cell line.

## Claims

### Claim 1

A cell line deposited under ATCC Accession No. PTA-10322.

### Claim 2

A human triple-negative breast cancer cell line, wherein the cell line comprises the following marker profile:
high expression of Snail-1 and Snail-2 (Slug); and
a p53 mutation in exon 8 at codon 273 (CGT>CAT).

### Claim 3 (depends on 2)

The cell line of claim 2, wherein the cell line is the cell line deposited under ATCC Accession No. PTA-10322.

### Claim 4

A human triple-negative breast carcinoma cell line, wherein a cell of said cell line produces a solid carcinoma upon subcutaneous implantation or injection into a non-human mammal, said cell line comprising the following marker profile:
high expression of Snail-1 and Snail-2 (Slug); and
a p53 mutation in exon 8 at codon 273 (CGT>CAT).

### Claim 5 (depends on 4)

The cell line of claim 4, wherein the cell line is the cell line deposited under ATCC Accession No. PTA-10322.

### Claim 6 (depends on 4)

The cell line of claim 4, wherein the non-human mammal is immune deficient.

### Claim 7 (depends on 4)

The cell line of claim 4, wherein the non-human mammal is a mouse.

### Claim 8 (depends on 2)

A solid tumor produced in a non-human mammal, wherein said tumor is produced by introducing into said mammal a cell of the human triple-negative breast cancer cell line of claim 2.

### Claim 9 (depends on 8)

The solid tumor of claim 8, wherein the non-human mammal has T-cell immunosuppression.

### Claim 10 (depends on 8)

The solid tumor of claim 8, wherein the human triple-negative breast cancer cell line is the cell line deposited under ATCC Accession No. PTA-10322.

### Claim 11 (depends on 8)

The solid tumor of claim 8, wherein the non-human mammal is immune deficient.

### Claim 12 (depends on 8)

The solid tumor of claim 8, wherein the non-human mammal is a mouse.

### Claim 13 (depends on 2)

A non-human mammal comprising one or more cells of a human triple-negative breast cancer cell line of claim 2.

### Claim 14 (depends on 13)

The non-human mammal of claim 13, wherein the cell line is the cell line deposited under ATCC Accession No. PTA-10322.

### Claim 15 (depends on 13)

The non-human mammal of claim 13, wherein the non-human mammal is immune deficient.

### Claim 16 (depends on 13)

The non-human mammal of claim 13, wherein the non-human mammal is a mouse.

### Claim 17 (depends on 2)

A method of producing a solid tumor in a non-human mammal, comprising:
introducing into said non-human mammal a cell of the human triple-negative breast cancer cell line of claim 2, wherein said cell produces a solid tumor in said mammal.

### Claim 18 (depends on 2)

A method for establishing a cell line derived from a human triple-negative breast cancer tumor, comprising
a) introducing into a non-human mammal a cell of the human triple-negative breast cancer cell line of claim 2,
wherein said cell produces a solid tumor in said non-human mammal;
b) removing said tumor from said non-human mammal; and
c) culturing cells of the tumor in a culture medium, thereby establishing a cell line derived from the human triple-negative breast cancer tumor.

### Claim 19 (depends on 2)

A method of identifying modulation of gene and/or protein expression and/or activity during breast cancer invasion, comprising:
a) introducing into a non-human mammal a cell of the human triple-negative breast cancer cell line of claim 2,
wherein said cell produces a solid tumor in said non-human mammal; and
b) identifying modulation of gene and/or protein expression and/or activity during breast cancer invasion resulting from the presence of said tumor.

### Claim 20 (depends on 19)

The method of claim 19, where the modulation of gene and/or protein expression and/or activity comprises modulation of gene copy number, miRNA levels and type, mRNA levels, protein levels, protein phosphorylation, and any combination thereof.

### Claim 21 (depends on 2)

A method of identifying modulation of gene expression during metastasis, comprising:
a) introducing into a non-human mammal a cell of the human triple-negative breast cancer cell line of claim 2, wherein said cell produces a solid tumor in said non-human mammal; and
b) identifying modulation in gene expression during metastasis resulting from the presence of said tumor.

### Claim 22 (depends on 2)

A method of identifying modulation in gene expression during epithelial to mesenchymal transition and mesenchymal to epithelial transition comprising:
a) introducing into a non-human mammal a cell of the human triple-negative breast cancer cell line of claim 2
wherein said cell produces a solid tumor in said non-human mammal; and
b) identifying modulation in gene expression during epithelial to mesenchymal transition and mesenchymal to epithelial transition resulting from the presence of said tumor.

### Claim 23 (depends on 2)

A method of identifying a chemotherapeutic agent having a therapeutic effect on a triple-negative breast cancer cell, comprising:
a) contacting a human triple-negative breast cancer cell from the cell line of claim 2 with a chemotherapeutic agent; and
b) determining if the chemotherapeutic agent inhibits proliferation of the triple-negative breast cancer cell, whereby identification of a chemotherapeutic agent that inhibits proliferation of the triple-negative breast cancer cell identifies a chemotherapeutic agent having a therapeutic effect on a triple-negative breast cancer cell.

### Claim 24 (depends on 2)

A method of identifying a chemotherapeutic agent having a therapeutic effect on triple-negative breast cancer, comprising:
a) introducing into a non-human mammal a cell of the human triple-negative breast cancer cell line of claim 2,
wherein said cell produces a solid tumor in said non-human mammal;
b) administering a chemotherapeutic agent to the non-human mammal with said solid tumor; and
c) determining if the chemotherapeutic agent inhibits proliferation of the tumor, whereby identification of a chemotherapeutic agent that inhibits proliferation of the tumor identifies a chemotherapeutic agent having a therapeutic effect on triple-negative breast cancer.

### Claim 25 (depends on 2)

A method of identifying a biological agent having a therapeutic effect on a triple-negative breast cancer cell, comprising
a) contacting a human triple-negative breast cancer cell from the cell line of claim 2 with a biological agent; and
b) determining if the biological agent inhibits the proliferation of the triple-negative breast cancer cell, whereby identification of a biological agent that inhibits proliferation of the triple-negative breast cancer cell identifies a biological agent having a therapeutic effect on a triple-negative breast cancer cell.

### Claim 26 (depends on 2)

A method of identifying a biological agent having a therapeutic effect on triple-negative breast cancer, comprising
a) introducing into a non-human mammal a cell of the human triple-negative breast cancer cell line of claim 2,
wherein said cell produces a solid tumor in said non-human mammal;
b) administering a biological agent to the non-human mammal with said solid tumor; and
c) determining if the biological agent inhibits proliferation of the solid tumor, whereby identification of a biological agent that inhibits tumor proliferation identifies a biological agent having a therapeutic effect on triple-negative breast cancer.

### Claim 27 (depends on 2)

A method of screening for modulators of gene expression, comprising:
a) measuring the level of gene expression in a cell from the cell line of claim 2;
b) contacting said cell with a candidate agent;
c) measuring the level of gene expression in said cell after contact with the candidate agent,
whereby a difference in the level of gene expression after contact with the candidate agent as compared to before contact with the candidate agent identifies a modulator of gene expression.
